Literature DB >> 30033836

Combination immunotherapy as a non-chemotherapy alternative for refractory or recurrent CNS lymphoma.

Prakash Ambady1, Laszlo Szidonya1, Jenny Firkins1, Jessica James1, Kirsten Johansson1, Tricia White1, Caroline Jezierski1, Nancy D Doolittle1, Edward A Neuwelt1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30033836      PMCID： PMC6342672          DOI： 10.1080/10428194.2018.1480771

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  12 in total

Review 1.  Combination strategies to enhance antitumor ADCC.

Authors:  Holbrook E Kohrt; Roch Houot; Aurélien Marabelle; Hearn Jay Cho; Keren Osman; Matthew Goldstein; Ronald Levy; Joshua Brody
Journal:  Immunotherapy       Date:  2012-05       Impact factor: 4.196

2.  Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma.

Authors:  C Soussain; F Suzan; K Hoang-Xuan; N Cassoux; V Levy; N Azar; C Belanger; E Achour; V Ribrag; S Gerber; J Y Delattre; V Leblond
Journal:  J Clin Oncol       Date:  2001-02-01       Impact factor: 44.544

3.  Autologous stem cell transplantation with thiotepa, busulfan, and cyclophosphamide (TBC) conditioning in patients with CNS involvement by non-Hodgkin lymphoma.

Authors:  Gregory M Cote; Ephraim P Hochberg; Alona Muzikansky; Fred H Hochberg; Jan Drappatz; Steven L McAfee; Tracy T Batchelor; Ann S LaCasce; David C Fisher; Jeremy S Abramson; Philippe Armand; Yi-Bin Chen
Journal:  Biol Blood Marrow Transplant       Date:  2011-07-13       Impact factor: 5.742

4.  Relapse of primary central nervous system lymphoma: clinical features, outcome and prognostic factors.

Authors:  Kristoph Jahnke; Eckhard Thiel; Peter Martus; Ulrich Herrlinger; Michael Weller; Lars Fischer; Agnieszka Korfel
Journal:  J Neurooncol       Date:  2006-05-13       Impact factor: 4.130

5.  PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma.

Authors:  Lakshmi Nayak; Fabio M Iwamoto; Ann LaCasce; Srinivasan Mukundan; Margaretha G M Roemer; Bjoern Chapuy; Philippe Armand; Scott J Rodig; Margaret A Shipp
Journal:  Blood       Date:  2017-03-29       Impact factor: 22.113

6.  Programmed death ligand 1 is expressed by non-hodgkin lymphomas and inhibits the activity of tumor-associated T cells.

Authors:  David J Andorsky; Reiko E Yamada; Jonathan Said; Geraldine S Pinkus; David J Betting; John M Timmerman
Journal:  Clin Cancer Res       Date:  2011-05-03       Impact factor: 12.531

7.  Most primary central nervous system diffuse large B-cell lymphomas occurring in immunocompetent individuals belong to the nongerminal center subtype: a retrospective analysis of 31 cases.

Authors:  Eyas M Hattab; Sarah E Martin; Sohaib M Al-Khatib; William J Kupsky; Gail H Vance; Ryan A Stohler; Magdalena Czader; Mousa A Al-Abbadi
Journal:  Mod Pathol       Date:  2009-11-20       Impact factor: 7.842

8.  Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire.

Authors:  Carole Soussain; Khê Hoang-Xuan; Luc Taillandier; Emmanuelle Fourme; Sylvain Choquet; Francis Witz; Olivier Casasnovas; Brigitte Dupriez; Bertrand Souleau; Anne-Laure Taksin; Christian Gisselbrecht; Arnaud Jaccard; Antonio Omuro; Marc Sanson; Maud Janvier; Brigitte Kolb; Jean-Marc Zini; Véronique Leblond
Journal:  J Clin Oncol       Date:  2008-04-14       Impact factor: 44.544

9.  Late relapses in primary CNS lymphoma after complete remissions with high-dose methotrexate monotherapy.

Authors:  Prakash Ambady; Matthias Holdhoff; David Bonekamp; Fay Wong; Stuart A Grossman
Journal:  CNS Oncol       Date:  2015-10-28

10.  Patterns of relapse in primary central nervous system lymphoma: inferences regarding the role of the neuro-vascular unit and monoclonal antibodies in treating occult CNS disease.

Authors:  Prakash Ambady; Rongwei Fu; Joao Prola Netto; Cymon Kersch; Jenny Firkins; Nancy D Doolittle; Edward A Neuwelt
Journal:  Fluids Barriers CNS       Date:  2017-06-02
View more
  5 in total

Review 1.  SOHO State of the Art Updates and Next Questions: Prophylaxis and Management of Secondary CNS Lymphoma.

Authors:  Jillian Simard; Mark Roschewski
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2022-06-06

2.  Relapsed and refractory primary CNS lymphoma: treatment approaches in routine practice.

Authors:  Prakash Ambady; Nancy D Doolittle; Christopher P Fox
Journal:  Ann Lymphoma       Date:  2021-09

3.  Primary central nervous system lymphoma: a narrative review of ongoing clinical trials and goals for future studies.

Authors:  Lauren R Schaff; Prakash Ambady; Nancy D Doolittle; Christian Grommes
Journal:  Ann Lymphoma       Date:  2021-03

Review 4.  Update on Novel Therapeutics for Primary CNS Lymphoma.

Authors:  Lauren R Schaff; Christian Grommes
Journal:  Cancers (Basel)       Date:  2021-10-26       Impact factor: 6.639

5.  Consensus recommendations for MRI and PET imaging of primary central nervous system lymphoma: guideline statement from the International Primary CNS Lymphoma Collaborative Group (IPCG).

Authors:  Ramon F Barajas; Letterio S Politi; Nicoletta Anzalone; Heiko Schöder; Christopher P Fox; Jerrold L Boxerman; Timothy J Kaufmann; C Chad Quarles; Benjamin M Ellingson; Dorothee Auer; Ovidiu C Andronesi; Andres J M Ferreri; Maciej M Mrugala; Christian Grommes; Edward A Neuwelt; Prakash Ambady; James L Rubenstein; Gerald Illerhaus; Motoo Nagane; Tracy T Batchelor; Leland S Hu
Journal:  Neuro Oncol       Date:  2021-07-01       Impact factor: 12.300
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.